Sfoglia per Autore  

Opzioni
Mostra risultati da 41 a 60 di 358
Titolo Data di pubblicazione Autore(i) File
Folfoxiri improves survival compared to folfiri as first-line treatment of metastatic colorectal cancer (MCRC): updated results of a randomized phase III study by the Gruppo Oncologico Nord Ovest (G.O.N.O.) 1-gen-2006 Masi, G.; Barbara, C.; Brunetti, I.; Pfanner, E.; Murr, R.; Ricci, S.; Benedetti, G.; Crinò, L.; Evangelista, W.; Berretto, O.; Picone, V.; Cortesi, E.; Vitello, S.; Chiara, S.; Granetto, C.; Merlano, M.; Fioretto, L.; Orlandini, C.; Andreuccetti, M.; Falcone, Alfredo
TREATMENT WITH 5FLUOROURACIL/FOLINIC ACID OXALIPLATIN AND IRINOTECAN ENABLES URGICAL RESECTION OF METASTASES IN PATIENTS WITH INITIALLY UNRESECTABLE METASTASTIC COLORECTAL CANCER 1-gen-2006 Masi, G; Cupini, S; Marcucci, L; Cerri, E; Loupakis, F; Allegrini, G; Brunetti, Im; Pfanner, E; Viti, M; Goletti, Orlando; Filipponi, Franco; Falcone, Alfredo
Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable colorectal cancer 1-gen-2006 Goletti, Orlando; Cupini, S.; L., Marcucci; E., Cerri; F., Loupakis; G., Allegrini; I., Brunetti; E., Pfanner; M., Viti; O., Goletti; Filipponi, Franco; Falcone, Alfredo
Capecitabine (C) in combination with Irinotecan (I) and Oxaliplatin (O) (XELOXIRI) in patients with metastatic colorectal cancer (MCRC): preliminary results of a pilot study by Gruppo Oncologico Nord Ovest (G.O.N.O.) 1-gen-2006 Bursi, S.; Masi, G.; Antonuzzo, A.; Cerri, E.; Loupakis, F.; Barbara, C.; Barletta, M.; Allegrini, G.; Cupini, S.; Ricci, S.; Brunetti, I.; Pfanner, E.; Lencioni, M.; Murr, R.; Petrini, Iacopo; Tognarini, L.; Andreuccetti, M.; Falcone, Alfredo
Sequential treatment with cisplatin (P) in combination with infusional 5-FU/LV (PFL) followed by Irinotecan (IR) + 5-FU/LV (IRFL) followed by Docetaxel (T) + 5-FU/LV (TFL) in patients (PTS) with metastatic (M) gastric carcinoma (GC): preliminary results of a phase II trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.) 1-gen-2006 Loupakis, F.; Masi, G.; Fontana, E.; Allegrini, G.; Bursi, S.; Barbara, C.; Cerri, E.; Barletta, M. T.; Picone, V.; Mentuccia, L.; Granetto, C.; Fea, E.; Pfanner, E.; Murr, R.; Brunetti, I.; Andreuccetti, M.; Falcone, Alfredo
Sequential treatment with cisplatin (P) in combination with infusional 5-FU/LV (PFL) followed by irinotecan (Ir) + 5-FU/LV (IrFL) followed by docetaxel (T) + 5-FU/LV (TFL) in patients (pts) with metastatic (M) gastric carcinoma (GC): Preliminary results of a phase II trial by the Gruppo Oncologico Nord-Ovest (G.O.N.O.) 1-gen-2006 Loupakis, F.; Masi, G.; Fontana, E.; Picone, V.; Mentuccia, L.; Granetto, C.; Fea, E.; Pfanner, E.; Lencioni, M.; Falcone, Alfredo
The combination of capecitabine (C), irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first line treatment of metastatic colorectal cancer (MCRC): Preliminary results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.) 1-gen-2007 Masi, G.; Bursi, S.; Loupakis, F.; Barletta, M.; Baldi, G.; Antonuzzo, A.; Sonaglio, C.; Pfanner, E.; Petrini, Iacopo; Falcone, Alfredo
First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine, irinotecan, and oxaliplatin (XELOXIRI): Preliminary results of a pilot study by the G.O.N.O. Group 1-gen-2007 Bursi, S.; Masi, G.; Loupakis, F.; Antonuzzo, A.; Tognarini, L.; Sonaglio, C.; Chiara, S.; Pfanner, E.; Brunetti, I.; Petrini, Iacopo; Baldi, G.; Barletta, M.; Allegrini, G.; Ricci, S.; Falcone, Alfredo
Pegfilgrastim to support chop-r chemotherapy administered every 14 days in the patients (pts) with aggressive b-cell non-hodgkin’s lymphoma (NHL) 1-gen-2007 Capochiani, E.; Cupini, S.; Loupakis, F.; Vasile, E.; Fontana, A.; Barbara, C.; Bursi, S.; Landi, L.; Coltelli, L.; Safina, V.; Barletta, M. T.; Baldi, G. G.; Giuntini, N.; LO DICO, M.; Mazzoni, E.; Masi, G.; Falcone, Alfredo
Capecitabine ( C ), in combination with irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI) as first-line treatment of metastatic colorectal cancer (MCRC): results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.) 1-gen-2007 Bursi, S.; Masi, G.; Loupakis, F.; Antonuzzo, A.; Chiara, S.; Pfanner, E.; Petrini, Iacopo; Barletta, M. T.; Baldi, G. G.; Falcone, Alfredo
Long-term outcome of unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line folfoxiri followed by r0 surgical resection of metastases 1-gen-2007 Masi, G.; Bursi, S.; Loupakis, F.; Barletta, M.; Barbara, C.; Vasile, E.; Cupini, S.; Brunetti, I.; Pfanner, E.; DI DONATO, S.; Dauria, G.; Fanchini, L.; Chiara, S.; Granetto, C.; Falcone, Alfredo
Long-term outcome of unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases 1-gen-2007 Masi, G.; Bursi, S.; Loupakis, F.; Barbara, C.; Brunetti, I.; Ferraldeschi, R.; Evangelista, W.; Chiara, S.; Granetto, C.; Falcone, Alfredo
Sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC) 1-gen-2007 Cupini, S.; Bursi, S.; Masi, G.; Loupakis, F.; Barbara, C.; Barletta, M. T.; Baldi, G. G.; Vasile, E.; Fornaro, L.; Petrini, Iacopo; Allegrini, G.; Antonuzzo, A.; DI MARSICO, R.; Andreuccetti, M.; Ricci, S.; Falcone, Alfredo
First-line folfoxiri followed by R0 surgical resection of metastases in unresectable metastatic colorectal cancer (MCRC) patients (pts) 1-gen-2007 Masi, G.; Loupakis, F.; Bursi, S.; Barbara, C.; Barletta, M. T.; Baldi, G.; Cupini, S.; Brunetti, I.; Pfanner, E.; Lencioni, M.; DI DONATO, S.; Mentuccia, L.; Fanchini, L.; Sonaglio, C.; Fea, E.; Allegrini, G.; Falcone, Alfredo
Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. 1-gen-2007 Loupakis, F.; Falcone, Alfredo; Masi, G.; Fioravanti, Anna; Kerbel, R. S.; Del Tacca, M.; Bocci, Guido
Phase II trial of sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC) 1-gen-2007 Cupini, S.; Bursi, S.; Masi, G.; Loupakis, F.; Barbara, C.; Fornaro, L.; Allegrini, G.; DI MARSICO, R.; Andreuccetti, M.; Falcone, Alfredo
Updated results, multivariate and subgroups analysis confirm improved activity and efficacy for FOLFOXIRI versus FOLFIRI in the G.O.N.O. randomized phase III study in metastatic colorectal cancer (MCRC) 1-gen-2007 Falcone, Alfredo; Andreuccetti, M.; Brunetti, I.; Ricci, S.; Barbara, C.; Evangelista, W.; Passeri, V.; Chiara, S.; Allegrini, G.; Masi, G.
First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine ( C ), irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI): a pilot study by the Gruppo Oncologico Nord Ovest (G.O.N.O.) 1-gen-2007 Bursi, S.; Masi, G.; Loupakis, F.; Antonuzzo, A.; Tognarini, L.; Sonaglio, C.; Chiara, S.; Pfanner, E.; Brunetti, I.; Petrini, Iacopo; Baldi, G. G.; Barletta, M. T.; Fornaro, L.; Allegrini, G.; Donati, S.; Andreuccetti, M.; Ricci, S.; Falcone, Alfredo
Phase II study of sequential chemotherapy with cisplatin (P) in combination with infusional 5FU/LV (PFL) followed by irinotecan (IR) + 5FU/LV (IrFL) followed by docetaxel (T) + 5FU/LV (TFL) in patients (pts) with metastatic gastric carcinoma (MGC) by the Gruppo Oncologico Nord-Ovest (GONO) 1-gen-2007 Loupakis, F.; Masi, G.; Bursi, S.; Picone, V.; Mentuccia, L.; Granetto, C.; Fea, E.; Murr, R.; Antonuzzo, A.; Falcone, Alfredo
Randomized phase III study of FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) vs FOLFIRI (irinotecan and 5FU/LV) as first-line treatment of metastatic colorectal cancer (MCRC): Subgroup and multivariate analysis 1-gen-2007 Falcone, Alfredo; Andreuccetti, M.; Orlandini, C.; Barbara, C.; Benedetti, G.; Evangelista, W.; Picone, V.; Chiara, S.; Granetto, C.; Masi, G.
Mostra risultati da 41 a 60 di 358
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile